All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Bookmark this article
In November 2018, Ellen McPhail from Mayo Clinic, MN, US, and colleagues, published in Haematologica a research study investigating the prognostic value of low-grade transformation, cytological characteristics (high-grade versus large-cell), cell of origin (CoO) and MYC rearrangements in the outcomes of double-/triple-hit lymphoma patients.
It is well-established that high-grade B-cell lymphoma with genetic rearrangements in MYC, BCL2 and/or BCL6 (double-/triple-hit [DH/TH]) presents with a very aggressive clinical phenotype and a varied cytological morphology. The possibility to use such cytological and genetic differences as prognostic markers of survival outcomes in DH/TH lymphoma patients remains unclear. The aim of this study was to address this likelihood in DH/TH lymphoma patients, by investigating overall survival (OS), event-free survival (EFS), and EFS12, defined as event-free status at 12 months following diagnosis.
These results indicate that subgroups within the DH/TH lymphoma category have different clinical outcomes, with patients transforming from low-grade lymphoma having an inferior OS when compared to patients with de novo DH/TH lymphoma. According to the authors, this study suggests that the genetic partners of MYC rearrangements have no prognostic value (IG versus non-IG gene) on the outcomes of patients with DH/TH lymphoma. Further research is needed to validate these interesting preliminary findings.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox